BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11421562)

  • 1. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.
    Gegick CG; Altheimer MD
    Endocr Pract; 2001; 7(3):162-9. PubMed ID: 11421562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
    Khan MA; St Peter JV; Xue JL
    Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors.
    Gegick CG; Altheimer MD
    Curr Med Res Opin; 2004 Jun; 20(6):919-30. PubMed ID: 15200751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thiazolidinediones: clinical data and perspectives].
    Blicklé JF
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):279-85. PubMed ID: 11452222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
    King AB
    Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
    Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
    Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
    King AB; Armstrong DU
    Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.
    Ko SH; Song KH; Ahn YB; Yoo SJ; Son HS; Yoon KH; Cha BY; Lee KW; Son HY; Kang SK
    Metabolism; 2003 Jun; 52(6):731-4. PubMed ID: 12800099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
    Gómez-Pérez FJ; Aguilar-Salinas CA; Vázquez-Chávez C; Fanghänel-Salmón G; Gallegos-Martínez J; Gómez-Diaz RA; Salinas-Orozco S; Chavira-López IJ; Sánchez-Reyes L; Torres-Acosta EM; Tamez R; López A; Guillén LE; Cesarman G
    Metabolism; 2002 Jan; 51(1):44-51. PubMed ID: 11782871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein effects of different thiazolidinediones in clinical practice.
    Ovalle F; Bell DS
    Endocr Pract; 2002; 8(6):406-10. PubMed ID: 15251829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S; Raskin P; Fonseca V; Graveline JF
    N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.